Today, we announced the European Commission’s approval of a new treatment option for #PulmonaryArterialHypertension (#PAH). Learn more: http://merck.us/4fWWIJ7
About us
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ
- Website
-
http://merck.us/2J2xAUh
External link for Merck
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Rahway, New Jersey
- Type
- Public Company
- Specialties
- Pharmaceutical
Locations
-
Primary
126 E Lincoln Ave
P.O. Box 2000
Rahway, New Jersey 07065, US
-
351 N Sumneytown Pike
North Wales, PA 19454, US
Employees at Merck
Updates
-
Despite the well-documented benefits of vaccines, hesitancy is a longstanding public health issue that can result in under-vaccination and global disease outbreaks. These challenges bring new opportunities to improve our approach and be better advocates for all our communities. Learn more about how we’re helping build vaccine confidence: http://merck.us/3MeJLfY
-
We're honored to be recognized on TIME's inaugural list of the World’s Most Sustainable Companies for our commitment to enabling a safe and healthy future for people and communities around the world. Learn more about our approach to positively impacting society and delivering long-term business value for all of our stakeholders in our 2023/2024 Impact Report: http://merck.us/4dEJG0W
-
-
Working on behalf of patients with rare diseases is a source of deep inspiration for us. We recognize the immense value of supportive communities for people with rare diseases, like #PAH. Every journey is different, but connecting and sharing the experience can make it less isolating. This weekend, we’re proud to join #PHA2024 and show our support for people living with #PAH and their families.
-
We build the bridges that connect our science with health care professionals and patients who need them. If you’re interested in being a part of this incredible journey, explore opportunities with us now: http://merck.us/3VCQrc7 #MerckCareers #LifeAtMerck
-
Today, we announced the acquisition of a novel investigational bispecific antibody from Curon Biopharmaceutical. Learn how this acquisition further expands and diversifies our growing pipeline, with potential applications in B-cell malignancies and autoimmune diseases: http://merck.us/3yuXiwQ
-
-
Listen to our newest episode of #CareerOnPurpose podcast as we speak with our chief diversity and inclusion officer Celeste Warren (She/Her) about our company’s efforts toward building an inclusive workforce. Check out the full episode to gain valuable insights about engaging talent from all backgrounds, education levels and job interests: http://merck.us/3Ahuit1
-
Congratulations to Jannie Oosthuizen, president of our Human Health U.S. business, for receiving an honorary doctorate in pharmacy from his alma mater North-West University for his global leadership and impact for patients! Jannie’s work over the last three decades has made a vital difference to people and communities around the world. We’re inspired by his continued commitment to helping our company deliver on our purpose of saving and improving lives.
-
-
Today, we announced that we’ve expanded our global development and commercialization agreement with Daiichi Sankyo US to include our investigational T-cell engager. This agreement builds upon and complements our companies’ shared commitment to developing novel medicines for patients living with #cancer. Read more here: http://merck.us/4fvVO69
Affiliated pages
Similar pages
Browse jobs
Stock
MRK
NYSE
20 minutes delay
$116.27
-0.33 (-0.283%)
- Open
- 116.73
- Low
- 116.16
- High
- 117.9
Data from Refinitiv
See more info on